Core Viewpoint - Haier Biomedical has transformed from a single low-temperature storage manufacturer to a comprehensive life sciences and medical innovation enterprise, with significant growth in new industries contributing to revenue [1][2]. Group 1: Financial Performance - In the first half of 2025, Haier Biomedical achieved operating revenue of 1.196 billion yuan and a net profit attributable to shareholders of 143 million yuan [1]. - The revenue share from new industries (smart medication, blood technology, laboratory solutions) increased from 38% in 2023 to 47% in 2025, a year-on-year increase of 7.27 percentage points [1][2]. Group 2: Industry Position and Innovations - The company holds over 50% market share in plasma collection solutions, maintaining its position as the leader in China [2]. - Haier Biomedical has upgraded its business model from "single equipment sales" to a comprehensive approach that includes smart devices, basic consumables, software platforms, and value-added services, enhancing customer loyalty and profitability [2]. Group 3: Research and Development - The company’s R&D investment increased by 11.61% year-on-year, accounting for 13.39% of operating revenue, focusing on AI technology integration and new product development [2]. Group 4: Market Expansion - Haier Biomedical's products are now available in over 150 countries and regions, with a 30% year-on-year increase in overseas revenue during the reporting period [3]. - The company has established localized platforms in five new countries, including Japan and Brazil, and anticipates growth in overseas markets due to the acceleration of medical infrastructure development in emerging markets [3].

青岛海尔生物医疗股份有限公司 第三届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、监事会会议召开情况 证券代码：688139 证券简称：海尔生物 公告编号：2025-043 （一） 审议通过《关于审议公司 2025 年半年度报告及摘要的议案》 经审议，公司监事会认为：公司 2025 年半年度报告及摘要的编制和审议程 序符合法律法规、《青岛海尔生物医疗股份有限公司章程》和公司内部管理制度 的各项规定。公司 2025 年半年度报告及摘要能够客观、真实地反映公司 2025 年半年度的经营情况，公司 2025 年半年度报告及摘要所披露的信息真实、准确、 完整，不存在任何虚假记载、误导性陈述或重大遗漏。 公司 2025 年半年度报告及摘要的内容详见与本公告同日在上海证券交易所 网站（http://www.sse.com.cn）披露的《青岛海尔生物医疗股份有限公司 2025 年半年度报告》和《青岛海尔生物医疗股份有限公司 2025 年半年度报告摘要》。 表决结果：同意 3 票，反对 0 票，弃权 0 ...

Core Viewpoint - The report outlines the progress and achievements of Qingdao Haier Biomedical Co., Ltd. in its "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" initiative for the first half of 2025, emphasizing the company's focus on AI integration, innovation, and market expansion to enhance competitiveness and shareholder value [1]. Group 1: Development and Innovation - The company accelerated the development of new productive forces, focusing on four major industries and enhancing global market competitiveness through an upgraded "four horizontal and four vertical" open R&D innovation system [1][2]. - The AI foundation is being strengthened with a multi-layered architecture that integrates AI technology with life sciences and medical innovation, resulting in the creation of 17 specialized intelligent agents across various fields [2][3]. - R&D investment reached 160 million yuan, accounting for 13.39% of revenue, with a 6% reduction in new product development cycles and a 48% increase in the number of invention patents [3]. Group 2: Product Solutions and Market Performance - In the low-temperature storage industry, the company launched innovative solutions focusing on automation and intelligence, achieving recognition from users and implementing various automated sample storage solutions across multiple institutions [4]. - The laboratory solutions sector saw breakthroughs with AI-driven automation, significantly improving the efficiency of PBMC separation and cell culture processes [4]. - The smart medication sector introduced several automated solutions, expanding services to over 300 medical institutions and achieving breakthroughs in overseas markets [5]. - The blood technology sector developed a new disposable leukocyte-reducing blood bag and an automated blood component separation machine, enhancing operational efficiency and safety for healthcare professionals [6]. Group 3: Market Expansion - Despite a 14.64% decline in domestic revenue to 761 million yuan, the company improved its market share in low-temperature storage and established a leading position in several new product categories [6][7]. - The overseas market showed strong growth, with revenue reaching 427 million yuan, a 30.17% increase year-on-year, and a 56.67% increase in the second quarter [7][8]. - The company implemented localized strategies in overseas markets, achieving significant product certifications and establishing local operational platforms in multiple countries [8]. Group 4: Corporate Governance and Investor Relations - The company enhanced its governance structure and compliance with legal regulations, holding multiple board meetings to ensure operational transparency and fairness [9][10]. - Investor relations activities included over 60 interactions with institutional investors, enhancing communication and transparency regarding the company's long-term value [10][11]. - The company has maintained a consistent dividend policy, with a total dividend payout of 788 million yuan since its listing, and initiated a new share repurchase plan to boost investor confidence [11][12]. Group 5: Employee Engagement and Incentives - The company adopted a "user value creation" model to maximize employee value, linking core staff incentives to company performance through a stock incentive plan [14].

证券代码：688139 证券简称：海尔生物 公告编号：2025-044 青岛海尔生物医疗股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 根据《上市公司募集资金监管规则》和《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》等相关规定，青岛海尔生物医疗股份有限公司 （以下简称"公司"、"本公司"或"海尔生物"）编制了《海尔生物 2025 年 半年度募集资金存放与使用情况专项报告》，具体如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经上海证券交易所科创板股票上市委员会2019年7月30日审核同意，并经中 国证券监督管理委员会2019年9月20日下发《关于同意青岛海尔生物医疗股份有 限公司首次公开发行股票注册的批复》（证监许可[2019]1742号）核准，同意海 尔生物公开发行人民币普通股不超过79,267,940股，每股发行价格为人民币 月22日到位，并经安永华明会计师事务所（特殊普通合伙）审验并出具了安永华 明（2019）验字第61433766_J04号验资报告。 （二） ...

Core Viewpoint - Haier Biomedical is experiencing significant growth driven by its diversified business model and technological advancements in the life sciences and medical device sectors, with a focus on low-temperature storage, smart medication, and laboratory solutions [2][8]. Group 1: Financial Performance - In the first half of 2025, Haier Biomedical reported a revenue of 1.196 billion yuan and a net profit attributable to shareholders of 143 million yuan [2]. - The revenue from new industries (smart medication, blood technology, laboratory solutions) increased from 38% in 2023 to 47% in the first half of 2025, marking a year-on-year increase of 7.27 percentage points [3]. Group 2: Industry Position and Innovations - Haier Biomedical holds a leading position in various segments, with its smart medication market share ranking among the top three in the industry, and over 50% market share in blood plasma collection solutions [4]. - The company has introduced innovative products such as a disposable leukocyte-reducing blood bag and an automated blood component separator, enhancing customer loyalty and profitability [4]. Group 3: Technological Advancements - The company has increased its R&D investment by 11.61%, accounting for 13.39% of its revenue, focusing on AI technology integration and new product development [6]. - Haier Biomedical has established a multi-layer AI infrastructure, enabling deep integration of AI with various applications, such as the IncGPT-Med model for smart medication [6][7]. Group 4: Growth Strategy - The growth strategy is based on optimizing industry structure, expanding overseas, and leveraging both internal development and external acquisitions [8][9]. - The company has expanded its presence to over 150 countries, with a notable 30% year-on-year increase in overseas revenue during the reporting period [8]. Group 5: Future Outlook - Haier Biomedical aims to enhance its global competitiveness by focusing on four major industries and accelerating the development of innovative products and solutions [9].

Core Viewpoint - Haier Biomedical is experiencing significant growth through its diversified industrial structure and digital transformation strategy, achieving a revenue of 1.196 billion yuan and a net profit of 143 million yuan in the first half of 2025, driven by the synergy of four major industries and AI technology [1] Group 1: Industrial Performance - The company has transformed from a single low-temperature storage manufacturer to a comprehensive life sciences and medical innovation enterprise, with new industries (smart medication, blood technology, laboratory solutions) accounting for 47% of revenue in the first half of 2025, up from 38% in 2023 [2] - Each industry has established a leading position in its respective segment, with the smart medication sector addressing hospital drug management inefficiencies and achieving a top-three market share in automated medication [3] - The blood technology sector holds over 50% market share in plasma collection, introducing new products that enhance customer loyalty and profitability [3][4] Group 2: Technological Advancements - The company is leveraging AI and digital technologies to create a competitive edge, with R&D investment increasing by 11.61% to 13.39% of revenue, focusing on AI integration and new product development [5] - A multi-layered AI architecture has been established, enabling deep integration of AI with various applications, such as the IncGPT-Med model that improves medication handling efficiency [5][6] - The company has seen a 48% increase in patent applications and has established two new R&D centers, reinforcing its technological barriers [6] Group 3: Growth Strategy - The growth potential of Haier Biomedical is driven by a combination of industrial structure optimization, overseas expansion, and internal and external growth strategies [7] - The company has expanded its presence to over 150 countries, with a 30% year-on-year increase in overseas revenue, particularly benefiting from localized strategies in emerging markets [7][8] - Continuous R&D investment and strategic acquisitions have strengthened the company's capabilities in low-temperature storage and laboratory solutions, while also rapidly building platforms in smart medication and blood technology [8]

Core Viewpoint - Haier Biomedical has transformed from a single low-temperature storage manufacturer to a comprehensive life sciences and medical innovation enterprise, covering low-temperature storage, smart medication, blood technology, and laboratory solutions [1] Financial Performance - For the first half of 2025, the company achieved operating revenue of 1.196 billion yuan and a net profit attributable to shareholders of 143 million yuan [1] Business Transformation - The revenue share from new industries (smart medication, blood technology, laboratory solutions, etc.) increased from 38% in 2023 to 47% in the first half of 2025, a year-on-year increase of 7.27 percentage points [1] International Expansion - The company's products are now available in over 150 countries and regions, with five new localized platforms established in Japan, Brazil, and others during the reporting period [1] - The localized strategy has shown significant results, with overseas revenue growing by over 30% year-on-year, and the second quarter's revenue scale and growth rate reaching a new high for 2023 [1]

格隆汇8月26日丨海尔生物(688139.SH)发布2025年半年度报告，报告期实现营业收入11.96亿元，同比下 降2.27%；归属上市公司股东的净利润1.43亿元，同比下降39.09%；扣除非经常性损益后的归属于上市 公司股东的净利润1.23亿元，同比下降41.68%；基本每股收益0.45元。 ...

证券代码：688139 证券简称：海尔生物 公告编号：2025-043 青岛海尔生物医疗股份有限公司 第三届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、监事会会议召开情况 青岛海尔生物医疗股份有限公司（以下简称"公司"、"本公司"或"海尔 生物"）第三届监事会第六次会议于 2025 年 8 月 26 日下午 14:00 以现场结合通 讯方式召开，现场会议在青岛市崂山区盈康一生大厦 19 楼会议室举行。本次会 议的通知于 2025 年 8 月 15 日以电子邮件方式送达全体监事。本次会议应出席监 事 3 人，实际出席监事 3 人，会议由江兰主持。会议的召集和召开程序符合有关 法律法规、规范性文件和公司章程的规定，会议决议合法、有效。 二、监事会会议审议情况 本次会议由江兰主持，经全体监事认真审议并表决，本次会议通过了如下议 案： （一） 审议通过《关于审议公司 2025 年半年度报告及摘要的议案》 公司 2025 年半年度报告及摘要的内容详见与本公告同日在上海证券交易所 网站（http:/ ...

青岛海尔生物医疗股份有限公司2025 年半年度报告 公司代码：688139 公司简称：海尔生物 青岛海尔生物医疗股份有限公司 2025 年半年度报告 * [16] A. A. K. 1 / 198 青岛海尔生物医疗股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险及应对措施，敬请查阅本 报告第三节"管理层讨论与分析"之"四、风险因素"。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人刘占杰、主管会计工作负责人莫瑞娟及会计机构负责人（会计主管人员）穆乃 娟声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 公司半年度报告中涉及公司未来计划、发展战略等前瞻性陈述，不构成公 ...